

Oncology Clinical Trials
Penn Medicine Lancaster General Health, Ann B. Barshinger Cancer Institute

	Study Title
BREAST	
Metamorph- Penn	Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer
GASTRIC	
SPOTLIGHT: 8951-CL-0301 ASTELLAS	Phase III, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus MFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
LUNG	
COAST MedImmune	A Phase 2, Open-label, Multicenter Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST)
NRG-LU005	Limited Stage Small Cell Lung Cancer(LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
OVARIAN	
NRG-GY009	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin And CTEP-Supplied Atezolizumab(IND#134427) Versus Pegulated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
DUO-O GOG Foundation AstraZeneca	A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
HEMATOLOGY	
Connect MDS and AML AZA-MDS-006 Celgene	The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
STOP-CA-Penn	Statins TO Prevent the Cardiotoxicity from Anthracyclines

Oncology Clinical Trials
Penn Medicine Lancaster General Health, Ann B. Barshinger Cancer Institute

	Study Title
OTHER	
EAY131-MATCH ECOG	Molecular Analysis for Therapy Choice (MATCH)
20170758 Amgen	A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects with non-myeloid Malignancies at High Risk for FN and Receiving Neulasta (pegfilgrastim) Onpro kit or Other Physician Choice Options for Prophylaxis of FN
PROMPT- Penn	Prospective Registry of MultiPlex Testing